AstraZeneca has been a driving force in CV science for more than 100 years and continues to be a pioneer in the industry, both with our current portfolio and innovation-rich pipeline. And so it’s with great excitement that we again have such a strong presence at this year’s ESC Congress in Barcelona, Spain, including data for patients with a history of heart attack.
At ESC 2017, we will not only be showcasing the positive impact of our medicines in the core CV disease areas as we know them, but will be showing how we are investing in the science to understand the progression of CV-related disease and identifying approaches to reduce CV risk.
Follow us on Twitter @AstraZeneca, and join the conversation #ESCCongress.
AstraZeneca’s approach to CVMD
people die each year from cardiovascular disease (CVD)
adults are currently living with diabetes
people have chronic kidney disease (CKD)
Science tells us to treat the CVMD patient as a whole so as to protect all relevant organs – including the heart, kidneys, and pancreas – and achieve sustainable treatment outcomes. This approach recognises the frequency of co-morbidities and the need to address CV, renal and metabolic core diseases and complications.
As a consequence, we are investigating these three disease areas and how they overlap. The insights gained from this research allow us to develop therapies that may advance the clinical management and improve the lives of CVMD patients.
It’s the way we work that makes us different. We are taking risks to lead the science in areas like cardiac regeneration, while also investing in large randomised clinical trials (including pragmatic trials) and real-world evidence research in both developed and emerging markets.
Myocardial infarction can take place after a CV event
We are working to increase the level of awareness on the risks of myocardial infarction occurring following an initial cardiovascular event
Veeva ID: Z4-6488
Date of next review: August 2018